Pharma Stories, Blogs, Interviews & Press Releases
Weekly Pharma Update: NEXPLANON Extension & Biosimilars
FDA Approves Extended-Use NEXPLANON® Implant What’s new: The U.S. Food and Drug Administration (FDA) approv...
Read Full StoryWeekly Pharma Update: Oral GLP-1 Launch & Deals
1) Novo Nordisk Begins U.S. Launch of Oral Wegovy® Weight-Loss Pill What’s new: Novo Nordisk has **official...
Read Full StoryWeekly Pharma Update (27 Dec–2 Jan 2026): FDA Approvals & GLP-1 Launch
1) FDA Approves Novo Nordisk’s Oral Wegovy® Pill What’s new: The U.S. FDA approved the first oral GLP-1 receptor agonis...
Read Full StoryWeekly Pharma Update – 15th to 27th December 2025
1) FDA Approves Lunsumio VELO™ for Subcutaneous Use in Follicular Lymphoma Date: 22 December 2025 What’s...
Read Full StoryWeekly Pharma Update — 8 to 13 December 2025
1) FDA Approves DAYBUE® STIX for Rett Syndrome (12 Dec 2025) What’s new: The U.S. FDA has given the green l...
Read Full StoryWeekly Pharma Update – (1-6th December 2025) - Global Approvals & Key Deals
1. Major Regulatory Approvals & Clinical Advancements BMS wins landmark FDA approval for first CAR-T in M...
Read Full StoryNEC, JFCR & Taiho to Develop Shared-Neoantigen Cancer Vaccines
NEC, together with the Japan Cancer Research Institute (JFCR) and Taiho Pharmaceutical, publicized a partnership to crea...
Read Full StoryFDA Approves Otsuka’s Voyxact for IgA Nephropathy (IgAN)
Otsuka's monoclonal antibody Voyxact has received FDA approval for the treatment of primary IgA nephropathy (IgAN) i...
Read Full StoryFDA Approves Durvalumab (Imfinzi) + FLOT Regimen for Resectable Gastric & GEJ Cancer
The U.S. FDA has given the green light to AstraZeneca’s durvalumab (Imfinzi) in combination with the FLOT chemothe...
Read Full StoryFDA Approves Novartis Gene Therapy Itvisma for Spinal Muscular Atrophy (SMA)
The U.S. FDA has granted Novartis' gene therapy Itvisma approval for the treatment of spinal muscular atrophy (SMA)...
Read Full StoryEMA CHMP Recommends 10 New Medicines for Approval
During its meeting from November 10 to 13 in the year 2025, the EMA-CHMP gave out a positive opinion which proposed the...
Read Full StoryBeta Drugs raises Rs 117 cr from HealthQuad and others
Beta Drugs a vertically integrated oncology-focused formulations company, has raised primary capital worth Rs 117 crore...
Read Full Story